Parsaclisib is a potent and selective PI3Kδ inhibitor, with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases.
Parsaclisib (INCB050465) is a potent and selective PI3Kδ with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases. Parsaclisib displays significant activity with IC50 values ranging from 0.2 to 2 nM in B and T cell proliferation aaasys. Parsaclisib inhibits proliferation of several DLBCL and MCL cell lines in vitro (EC50 < 10 nM)[1].
[1]. Niu Shin, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15).